Abdominal aortic aneurysm (AAA) is one of cardiovascular medicine’s most deceptive killers. The disease involves a localized, tumor-like dilation of the abdominal aorta that typically progresses without symptoms until the vessel wall thins to the point of catastrophic rupture. As the aneurysm expands beyond roughly 5 centimeters, the aortic wall undergoes progressive structural degradation, leaving it vulnerable to abrupt tearing triggered by blood pressure spikes, physical exertion, or trauma. Once rupture occurs, mortality is exceedingly high, which is why researchers have long sought molecular clues that could enable earlier diagnosis and preventive treatment. A new study published in iScience by Yajing Li, Bin Zheng and colleagues at Hebei Medical University now identifies an unexpected player in this process: MTR4, a Ski2-like RNA helicase best known for its housekeeping role in RNA surveillance and degradation, emerges as a driver of vascular smooth muscle cell senescence and aneurysm progression through a signaling pathway not previously linked to the disease.

The research team began by interrogating publicly available RNA-sequencing data and human surgical specimens, and the results were striking. MTR4 transcripts were significantly elevated in aneurysmal aortas compared with non-diseased vessels, and immunohistochemistry and immunofluorescence confirmed markedly higher MTR4 protein abundance in the aneurysmal wall, with staining concentrated predominantly in the medial layer of the vessel. To extend these observations to an experimental setting, the investigators established the classic angiotensin II (Ang II)-induced AAA model, in which ApoE-deficient mice maintained on a high-cholesterol diet receive continuous Ang II infusion via subcutaneously implanted osmotic minipumps. Ultrasound imaging, aortic weight-to-body-weight ratios, and histopathology with Elastica van Gieson and Masson’s trichrome staining confirmed robust aneurysm induction, characterized by severe elastin fragmentation and collagen deposition. Crucially, both immunoblotting and quantitative RT-PCR revealed significant upregulation of MTR4 protein and mRNA in murine aneurysmal tissue. Co-immunofluorescence staining then localized the upregulation: MTR4 co-localized strongly with α-smooth muscle actin in the medial smooth muscle layer but showed minimal overlap with the macrophage marker CD68, indicating that the pathological increase occurs mainly in vascular smooth muscle cells rather than infiltrating immune cells.

With MTR4’s expression pattern established, the team turned to the senescence landscape of aneurysmal tissue, a plausible connection given growing evidence that vascular smooth muscle cell (VSMC) aging accelerates AAA. RNA sequencing of abdominal aortic tissues from control and aneurysm mice detected 16,889 transcripts upregulated in AAA, and functional annotation revealed that 5,149 of these were senescence-related, highlighting aging programs as a prominent biological signature of aneurysm formation. Immunohistochemistry demonstrated robust upregulation of the canonical senescence markers p16, p21, and p53 in both human AAA tissues and murine aneurysmal aortas, corroborated at the transcript and protein levels by qRT-PCR and immunoblotting. Because advanced age is a major risk factor for AAA, the researchers also induced aneurysms with calcium phosphate in young (8-week-old) and aged (24-week-old) C57BL/6 mice. The aged animals displayed substantially more severe aneurysmal remodeling, with pronounced elastic lamellar fragmentation, greater luminal dilatation, medial wall thinning, and increased p16 expression. Correlation analysis in human samples further showed significant positive linear relationships between MTR4 expression and p16, p21, and p53, strongly suggesting that MTR4 participates in senescence regulation within the aneurysmal wall. The senescence connection also extended to a second vascular disease: in atherosclerotic vessels, MTR4 was again elevated and co-localized with α-SMA, with senescence markers rising in parallel.

To move from association to causation, the team generated MTR4-deficient mice crossed onto the ApoE-deficient background to obtain double-knockout animals, which were then subjected to Ang II infusion. Genetic ablation of MTR4 markedly reduced Ang II-induced aneurysm formation compared with ApoE-deficient controls. Histological analysis showed that MTR4 deficiency preserved aortic wall architecture, with substantially less elastin disorganization and reduced extracellular matrix remodeling. Consistent with this protection, deletion of MTR4 significantly blunted the Ang II-induced upregulation of p16 and p21, as assessed by western blotting, qRT-PCR, and immunohistochemistry. In cultured VSMCs, the reciprocal experiments told a complementary story: silencing MTR4 reduced basal expression of p16, p21, and p53 at both mRNA and protein levels and largely abrogated their induction by Ang II, while senescence-associated β-galactosidase (SA-β-gal) staining showed that MTR4 depletion attenuated Ang II-triggered senescence. Conversely, forced MTR4 expression via adenoviral vectors produced a marked accumulation of SA-β-gal-positive cells, an effect potentiated by co-treatment with Ang II, indicating a synergistic pro-senescent action. Importantly, neither knockdown nor overexpression significantly altered VSMC viability in the CCK-8 assay, suggesting that MTR4 regulates cellular aging rather than cytotoxicity.

The mechanistic heart of the study came from pathway analysis. Re-analyzing RNA-seq data from Ang II-stimulated VSMCs following MTR4 silencing, KEGG enrichment identified Rap1 signaling as one of the most significantly affected pathways. Rap1 proteins are small GTPases of the Ras superfamily that cycle between inactive GDP-bound and active GTP-bound states, functioning as molecular switches that convert extracellular cues into downstream effector responses, with their activation controlled by guanine nucleotide exchange factors including the RASGRP family. Immunoblotting revealed that MTR4 depletion significantly reduced RAP1A protein abundance while increasing RASGRP2, whereas MTR4 overexpression produced the opposite pattern, upregulating RAP1a and decreasing RASGRP2. Time-course experiments showed that Ang II progressively increased RAP1a expression in VSMCs while leaving RASGRP2 largely unaffected, and in vivo, RAP1a abundance was elevated in aneurysmal aortas from wild-type MTR4 mice but sharply blunted in MTR4-deficient animals. These converging results nominated RAP1a as the principal Rap1-pathway effector linked to MTR4 during aneurysm development.

To probe how an RNA helicase might regulate RAP1a, the researchers performed actinomycin D chase experiments and co-immunoprecipitation assays. MTR4 did not affect the stability of Rap1a mRNA, ruling out transcriptional or mRNA-stability regulation, but the co-immunoprecipitation data revealed a physical protein interaction between MTR4 and Rap1a that weakened upon MTR4 knockdown. Combined with MTR4’s positive effect on RAP1a protein abundance, the authors propose that MTR4 maintains Rap1a protein levels through post-translational modulation via protein-protein interaction, a hypothesis they intend to refine with future RNA immunoprecipitation studies examining whether translational regulation is also involved.

Functional epistasis experiments then cemented RAP1a’s role as the downstream mediator. Silencing RAP1a with siRNA substantially attenuated Ang II-induced upregulation of senescence-associated genes and proteins and significantly reduced SA-β-gal-positive cells, whereas RAP1a overexpression alone increased SA-β-gal positivity under Ang II stimulation, recapitulating the effect of MTR4 overexpression. Critically, when the team overexpressed MTR4 while simultaneously depleting RAP1a, the pro-senescent effect of MTR4 was largely reversed under Ang II stimulation. The reciprocal experiment sealed the causal chain: MTR4 knockdown suppressed Ang II-induced senescence, and this suppression was rescued by forced RAP1a expression, as evidenced by restored SA-β-gal positivity. Enzyme-linked immunosorbent assays added an inflammatory dimension, showing that MTR4 knockdown decreased secretion of the senescence-associated secretory phenotype factors IL-6 and MMP-9 in VSMC culture supernatants, with the reduction partially restored by RAP1a overexpression in the MTR4-depleted background.

The findings carry broader significance beyond aneurysm biology. MTR4 is a central activator of the RNA exosome, the cellular machinery that degrades aberrant or unwanted RNA substrates, and it participates in distinct complexes that target promoter upstream transcripts, enhancer RNAs, and prematurely terminated RNAs for degradation. The new work reveals that this RNA surveillance factor can also modulate VSMC senescence through the Rap1 pathway, thereby mediating AAA formation, and suggests that MTR4 may act as a senescence regulator across multiple age-related vascular diseases. Notably, this is the first study to link Rap1a activation with VSMC senescence and AAA progression, enriching the pathological significance of Rap1 signaling in vascular disease beyond its previously documented roles in atherosclerosis, vascular calcification, and cell migration. Because atherosclerosis and AAA share chronic inflammation, vascular remodeling, and VSMC senescence despite differing in their underlying pathology, targeting MTR4 could hold therapeutic value across several conditions.

The authors are careful to acknowledge limitations. The study measured total Rap1 protein rather than the GTP-bound active fraction, and future Rap1-GTP pull-down assays will be needed to directly quantify pathway activation. The in vitro monoculture system cannot fully recapitulate the multicellular complexity of the aneurysmal wall, and partial recovery of RASGRP2 in MTR4 knockout mice points to additional MTR4-independent regulatory mechanisms. Only male mice were used, an important caveat given the well-documented sex differences in AAA prevalence and rupture risk, and a two-sample Mendelian randomization analysis using GTEx artery-aorta eQTLs and a public GWAS dataset yielded only suggestive genetic evidence: the weighted median estimator indicated a positive causal effect of MTR4 expression on AAA risk (odds ratio 1.07, 95% confidence interval 1.006–1.14, p = 0.032), but the primary inverse-variance weighted analysis did not reach significance, likely reflecting limited statistical power from a small set of instrumental variables.

Even with these caveats, the study opens concrete translational avenues. The authors propose developing specific MTR4 inhibitors or Rap1 pathway modulators and evaluating their efficacy in preclinical AAA models, as well as exploring MTR4 as a diagnostic or prognostic biomarker to identify high-risk patients before rupture. Raw RNA-sequencing data from the study have been deposited in NCBI BioProject under accession numbers PRJNA1419531 and PRJNA1419767, and uncropped microscopy images are available through Zenodo, supporting reproducibility. For a disease that often announces itself only through a life-threatening emergency, the identification of an RNA helicase-driven senescence axis offers a genuinely new molecular foothold, one that could ultimately shift abdominal aortic aneurysm from a surgical emergency toward a condition that can be anticipated, monitored, and pharmacologically slowed.

Subject of Research: The role of the RNA helicase MTR4 and the RAP1a signaling axis in vascular smooth muscle cell senescence and abdominal aortic aneurysm progression

Subject of Research: Technology and Engineering

Article Title: MTR4 deficiency attenuates abdominal aortic aneurysm progression through suppressing VSMC senescence via the MTR4-RAP1a axis

Article References: Li, Y., Tian, K., Wang, Y., Wu, S., Cao, Q., Wang, S., Zhang, X., Wang, X., Lian, H., Liu, X., Hao, Y., Wang, W., Zhao, L., Yu, Q., Zhang, L., Zhang, Y., Wen, J., & Zheng, B. (2026). MTR4 deficiency attenuates abdominal aortic aneurysm progression through suppressing VSMC senescence via the MTR4-RAP1a axis. iScience, 29(10), Article 117498. https://doi.org/10.1016/j.isci.2026.117498

Image Credits: AI Generated

DOI: 10.1016/j.isci.2026.117498

Keywords: abdominal aortic aneurysm, MTR4, RAP1a, vascular smooth muscle cell senescence, Rap1 signaling pathway, RNA exosome, angiotensin II, p16, p21, p53, atherosclerosis, senescence-associated secretory phenotype

Cite Scienmag News
APA MLA Chicago

Beatrice Stafford. (September 11, 2026). MTR4 loss slows aortic aneurysm growth by curbing vascular smooth muscle senescence. Scienmag. https://scienmag.com/mtr4-loss-slows-aortic-aneurysm-growth-by-curbing-vascular-smooth-muscle-senescence/

Copy citation Download RIS

Tags: abdominal aortic aneurysm progressionaneurysm rupture risk factorsAortic aneurysm molecular mechanismsAortic aneurysm progressionearly diagnosis biomarkers for AAAgene expression profiling in aneurysm tissuesmolecular diagnosis of aneurysm rupture riskmolecular insights into aneurysm growthmolecular mechanisms of abdominal aortic aneurysmmolecular signaling pathways in aneurysm developmentMTR4 RNA helicaseMTR4 RNA helicase role in cardiovascular diseasepreventive treatments for aortic aneurysmRNA degradation and vascular healthRNA degradation pathways in vascular biologyRNA surveillance in cardiovascular diseaseRNA surveillance in vascular pathologyrole of MTR4 in vascular smooth muscle cellssignaling pathways in aortic dilationtherapeutic targets for AAA preventionvascular smooth muscle cell senescencevascular wall structural degradation